NEW YORK (GenomeWeb) – Myriad Genetics announced after the close of the market Tuesday that its board of directors has approved an additional $200 million authorization for the firm's share repurchase program.

The company's previous share repurchase program began in 2010, and since then Myriad has repurchased nearly $1 billion of its stock. The repurchases are made via the open market or through privately negotiated purchases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.